818 related articles for article (PubMed ID: 18923524)
61. ALK amplification and protein expression predict inferior prognosis in neuroblastomas.
Wang M; Zhou C; Sun Q; Cai R; Li Y; Wang D; Gong L
Exp Mol Pathol; 2013 Oct; 95(2):124-30. PubMed ID: 23797004
[TBL] [Abstract][Full Text] [Related]
62. Cell culture modeling of genotype-directed sensitivity to selective kinase inhibitors: targeting the anaplastic lymphoma kinase (ALK).
Settleman J
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S36-41. PubMed ID: 19393834
[TBL] [Abstract][Full Text] [Related]
63. Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors.
Bossi RT; Saccardo MB; Ardini E; Menichincheri M; Rusconi L; Magnaghi P; Orsini P; Avanzi N; Borgia AL; Nesi M; Bandiera T; Fogliatto G; Bertrand JA
Biochemistry; 2010 Aug; 49(32):6813-25. PubMed ID: 20695522
[TBL] [Abstract][Full Text] [Related]
64. Generation of conditional ALK F1174L mutant mouse models for the study of neuroblastoma pathogenesis.
Ono S; Saito T; Terui K; Yoshida H; Enomoto H
Genesis; 2019 Oct; 57(10):e23323. PubMed ID: 31218818
[TBL] [Abstract][Full Text] [Related]
65. Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma.
Santo EE; Ebus ME; Koster J; Schulte JH; Lakeman A; van Sluis P; Vermeulen J; Gisselsson D; Øra I; Lindner S; Buckley PG; Stallings RL; Vandesompele J; Eggert A; Caron HN; Versteeg R; Molenaar JJ
Oncogene; 2012 Mar; 31(12):1571-81. PubMed ID: 21860421
[TBL] [Abstract][Full Text] [Related]
66. Partial deletion of the ALK gene in ALK-positive anaplastic large cell lymphoma.
Fukuhara S; Nomoto J; Kim SW; Taniguchi H; Miyagi Maeshima A; Tobinai K; Kobayashi Y
Hematol Oncol; 2018 Feb; 36(1):150-158. PubMed ID: 28665006
[TBL] [Abstract][Full Text] [Related]
67. Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma.
Regairaz M; Munier F; Sartelet H; Castaing M; Marty V; Renauleaud C; Doux C; Delbé J; Courty J; Fabre M; Ohta S; Vielh P; Michiels S; Valteau-Couanet D; Vassal G
Am J Pathol; 2016 Feb; 186(2):435-45. PubMed ID: 26687816
[TBL] [Abstract][Full Text] [Related]
68. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.
Murugan AK; Xing M
Cancer Res; 2011 Jul; 71(13):4403-11. PubMed ID: 21596819
[TBL] [Abstract][Full Text] [Related]
69. Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels.
Duijkers FA; Gaal J; Meijerink JP; Admiraal P; Pieters R; de Krijger RR; van Noesel MM
Cell Oncol (Dordr); 2011 Oct; 34(5):409-17. PubMed ID: 21625996
[TBL] [Abstract][Full Text] [Related]
70. Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.
Chen L; Humphreys A; Turnbull L; Bellini A; Schleiermacher G; Salwen H; Cohn SL; Bown N; Tweddle DA
Oncotarget; 2016 Dec; 7(52):87301-87311. PubMed ID: 27888620
[TBL] [Abstract][Full Text] [Related]
71. Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis.
Lopez-Delisle L; Pierre-Eugène C; Louis-Brennetot C; Surdez D; Raynal V; Baulande S; Boeva V; Grossetête-Lalami S; Combaret V; Peuchmaur M; Delattre O; Janoueix-Lerosey I
Oncogene; 2018 Mar; 37(11):1417-1429. PubMed ID: 29321660
[TBL] [Abstract][Full Text] [Related]
72. Novel TENM3-ALK fusion is an alternate mechanism for ALK activation in neuroblastoma.
Hiwatari M; Seki M; Matsuno R; Yoshida K; Nagasawa T; Sato-Otsubo A; Yamamoto S; Kato M; Watanabe K; Sekiguchi M; Miyano S; Ogawa S; Takita J
Oncogene; 2022 May; 41(20):2789-2797. PubMed ID: 35411036
[TBL] [Abstract][Full Text] [Related]
73. ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation.
Borenäs M; Umapathy G; Lai WY; Lind DE; Witek B; Guan J; Mendoza-Garcia P; Masudi T; Claeys A; Chuang TP; El Wakil A; Arefin B; Fransson S; Koster J; Johansson M; Gaarder J; Van den Eynden J; Hallberg B; Palmer RH
EMBO J; 2021 Feb; 40(3):e105784. PubMed ID: 33411331
[TBL] [Abstract][Full Text] [Related]
74. Emergence of new ALK mutations at relapse of neuroblastoma.
Schleiermacher G; Javanmardi N; Bernard V; Leroy Q; Cappo J; Rio Frio T; Pierron G; Lapouble E; Combaret V; Speleman F; de Wilde B; Djos A; Ora I; Hedborg F; Träger C; Holmqvist BM; Abrahamsson J; Peuchmaur M; Michon J; Janoueix-Lerosey I; Kogner P; Delattre O; Martinsson T
J Clin Oncol; 2014 Sep; 32(25):2727-34. PubMed ID: 25071110
[TBL] [Abstract][Full Text] [Related]
75. Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.
Siaw JT; Wan H; Pfeifer K; Rivera VM; Guan J; Palmer RH; Hallberg B
Oncotarget; 2016 May; 7(20):29011-22. PubMed ID: 27049722
[TBL] [Abstract][Full Text] [Related]
76. Targeted Therapy for Neuroblastoma: ALK Inhibitors.
Schulte JH; Schulte S; Heukamp LC; Astrahantseff K; Stephan H; Fischer M; Schramm A; Eggert A
Klin Padiatr; 2013 Nov; 225(6):303-8. PubMed ID: 24166094
[TBL] [Abstract][Full Text] [Related]
77. Neuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma.
Satoh S; Takatori A; Ogura A; Kohashi K; Souzaki R; Kinoshita Y; Taguchi T; Hossain MS; Ohira M; Nakamura Y; Nakagawara A
Sci Rep; 2016 Sep; 6():32682. PubMed ID: 27604320
[TBL] [Abstract][Full Text] [Related]
78. Inhibitors of anaplastic lymphoma kinase: a patent review.
Milkiewicz KL; Ott GR
Expert Opin Ther Pat; 2010 Dec; 20(12):1653-81. PubMed ID: 20961208
[TBL] [Abstract][Full Text] [Related]
79. Targeting anaplastic lymphoma kinase in neuroblastoma.
Umapathy G; Mendoza-Garcia P; Hallberg B; Palmer RH
APMIS; 2019 May; 127(5):288-302. PubMed ID: 30803032
[TBL] [Abstract][Full Text] [Related]
80. Emerging importance of ALK in neuroblastoma.
Azarova AM; Gautam G; George RE
Semin Cancer Biol; 2011 Oct; 21(4):267-75. PubMed ID: 21945349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
